hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported 3 hours ago - Updated 3 hours ago - 1 reports

Lymphoma Research Foundation Announces New Scientific Advisory Board Members

The Lymphoma Research Foundation (LRF) has announced the election of six experts in the field of lymphoma research to its prestigious Scientific Advisory Board (SAB). Comprised of the world's leading lymphoma researchers and oncologists, the Scientific ... [Published Industrial Info Financials - 3 hours ago]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

System 'prints' precise drug dosages tailored for patients

Arun Giridhar, an associate research scientist in Purdue's School of Chemical Engineering, works with student Sierra Davis to operate a prototype system to dispense precise medication dosages tailored for specific patients, an advance in personalized ... [Published Purdue University - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Eutropics Laboratory Receives CLIA Certification

Eutropics, a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, recently announced that its clinical diagnostics laboratory, located in Cambridge, Mass., has received CLIA ... [Published Advance for Administrators of the Laboratory - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Well-Differentiated Thyroid Cancer: Radiation Found to Increase Risk of Secondary Hematologic Malignancy—Clinical Significance, Though, Remains to be Determined

Image ToolsFor patients with well-differentiated thyroid cancer (WDTC), use of radiation therapy increases the risk of developing a secondary hematologic malignancy by 27 percent—mainly attributable to a 32 percent increased risk associated with radioactive ... [Published Oncology Times - Jul 18 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 1 reports

Actinium Bolsters Scientific Advisory Board

Actinium Pharmaceuticals reported the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board for Iomab-B. Iomab-B, the Company's lead radioimmunotherapy asset, is entering a Phase 3 trial to potentially address the rapid mortality and ... [Published Individual.com - Jul 10 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 1 reports

Baylor Oncology Medical Director Joins Actinium’s Iomab-B Scientific Advisory Board

NEW YORK--(BUSINESS WIRE)-- (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition of M. Yair Levy, MD of ... [Published Investor's Business Daily - Jul 07 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Events identified that cause bone marrow inflammation leading to blood disorders

Ratings require JavaScript to be enabled.Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia ... [Published Medical News Today - Jul 08 2014]
First reported Jul 04 2014 - Updated Jul 04 2014 - 1 reports

Biochemical cascade causes bone marrow inflammation, leading to serious blood disorders

INDIANAPOLIS -- Like a line of falling dominos, a cascade of molecular events in the bone marrow produces high levels of inflammation that disrupt normal blood formation and lead to potentially deadly disorders including leukemia, an Indiana University-led ... [Published Bio-Medicine - Jul 04 2014]
First reported Jul 02 2014 - Updated Jul 02 2014 - 1 reports

Massachusetts General Hospital Details Findings in Stem Cells (Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem...

Massachusetts General Hospital Details Findings in Stem Cells (Treatment of Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation)By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report ... [Published HispanicBusiness.com - Jul 02 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Bringing Palliative and Hematologic Malignancy Care Together

Betty R. Ferrell, PhD, RNDisclosures June 16, 2014 Bridging the Gap: A Palliative Care Consultation Service in a Hematological Malignancy–Bone Marrow Transplant UnitSelvaggi KJ, Vick JB, Jessell SA, Lister J, Abrahm JL, Bernacki RJ Commun Support Oncol. ... [Published American Journal of Public Health - Jun 16 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 1 reports

Eutropics Laboratory Receives CLIA Certification

"With CLIA certification, Eutropics has proven capability in executing complex testing in a highly regulated environment. Our platform technology is now ready for hematology oncology clinicians to guide selection of treatment options that will best help ... [Published Cincinnati.com - Jun 16 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ... [Published Marketwire - Breaking News Releases - Jun 12 2014]

Quotes

"The Lymphoma Research Foundation's Scientific Advisory Board is comprised of the preeminent lymphoma specialists in the world and we are thrilled to have these six prominent individuals lend their expertise and talents to our Scientific Advisory Board" said LRF Chief Executive Officer Elizabeth Thompson
"Pharmaceutical companies make one or two or three dosage levels, so people try breaking tablets in half and other methods to get toto the right dosage" said Gintaras "Rex" Reklaitis , Purdue University's Burton and Kathryn Gedge Distinguished Professor of Chemical Engineering
...director of the Acute and Chronic Leukemia Program, Division of Hematology, Mayo Clinic and Mayo Clinic Cancer Center, Scottsdale, who also added, "Obtaining CLIA certification is a significant milestone in the process of bringing this technology to patients."
Kaushik J Dave, Ph D , President and CEO of the Company stated, "We are gratified to add Dr. Levy to our newly formed SAB, which includes experts in the field of oncology, hematology, and bone marrow transplant. Texas Oncology is one of the largest oncology practices in the nation treating over 55,000 cancer patients every year, and Dr. Levy's affiliation brings valuable perspective to the transplant physicians on our SAB as he is an experienced clinical trial researcher. The Texas Oncology-Baylor Charles A Sammons Cancer Center is one of the ten largest bone marrow transplant centers in the United States."

More Content

All (17) | News (16) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Lymphoma Research Foundation Announces New Scie... [Published Industrial Info Financials - 3 hours ago]
System 'prints' precise drug dosages tailored f... [Published Purdue University - Jul 18 2014]
Eutropics Laboratory Receives CLIA Certification [Published Advance for Administrators of the Laboratory - Jul 18 2014]
Well-Differentiated Thyroid Cancer: Radiation F... [Published Oncology Times - Jul 18 2014]
Actinium Bolsters Scientific Advisory Board [Published Individual.com - Jul 10 2014]
Events identified that cause bone marrow inflam... [Published Medical News Today - Jul 08 2014]
Baylor Oncology Medical Director Joins Actinium... [Published Investor's Business Daily - Jul 07 2014]
Biochemical cascade causes bone marrow inflamma... [Published Bio-Medicine - Jul 04 2014]
Biochemical cascade causes bone marrow inflamma... [Published EurekAlert! - Jul 03 2014]
Massachusetts General Hospital Details Findings... [Published HispanicBusiness.com - Jul 02 2014]
ASCO Presidents Survey 50 Years of Oncology [Published American Journal of Public Health - Jun 23 2014]
AGIOS PHARMACEUTICALS : Posts Clinical Data fro... [Published 4 Traders - Jun 18 2014]
Bringing Palliative and Hematologic Malignancy ... [Published American Journal of Public Health - Jun 16 2014]
Eutropics Laboratory Receives CLIA Certification [Published Cincinnati.com - Jun 16 2014]
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ImmunoGen Inc. Announces Favorable Initial Safe... [Published BioPortfolio - Dec 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.